Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
General Internal Medicine
Hodgkin Lymphoma
Questions discussed in this category
What factors should be considered when deciding whether to omit radiation in pediatric/AYA patients receiving N+AVD, particularly regarding long-term outcomes and second malignancy risks?
1 Answer available
23228
Papers discussed in this category
The New England journal of medicine, 2024 Oct 17
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
Related Topics in General Internal Medicine
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Oncology
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers
